The Risk of Uveitis in AS Treated with TNF Blockers Save

Claims data analysis of 2115 ankylosing spondylitis patients without uveitis who started TNF inhibitor therapy revealed that the median time to the onset of uveitis was longest for those taking adalimumab (243 days), followed by etanercept (182 days) and infliximab (144 days). The incidence rate for uveitis over 1 year was lowest for patients who received adalimumab (2.4%), highest for patients who received etanercept (4.5%) and intermediate for patients who received infliximab (3.2%). There was no significant difference between adalimumab and infliximab rates.